SEARCH

SEARCH BY CITATION

References

  • 1
    Kerner J. Das Fettgift oder die Fettsäure und ihre Wirkungen auf den thierischen Organismus ein Beytrag zur Untersuchung des in verdobenen Würsten giftig wirkenden Stoffes. Stuttgart, Tübingen: Cotta, 1822.
  • 2
    Van Ermengen EPM. Contributions à l'étude des intoxications alimentaires. Recherches sur des accidents à caractères botuliniques provoqués par du jambon. Arch Pharmacodyn 1897; 0: 23150, 499–601.
  • 3
    Scott AB. Botulinum toxin injections into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980; 87: 10449.
  • 4
    Greene P, Kang U, Fahn S, Brin MF, Moskovitz C, Flaster E. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 1990; 40: 12138.
  • 5
    Brin MF, Blitzer A, Fahn S, Gould W, Lovelace RE. Adductor laryngeal dystonia (spastic dysphonia): treatment with local injections of botulinum toxin (Botox). Mov Disord 1989; 4: 28796.
  • 6
    Rivest J, Lees AJ, Marsden CD. Writer's cramp: treatment with botulinum toxin injections. Mov Disord 1990; 6: 559.
  • 7
    Jankovich J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991; 324: 118694.
  • 8
    Brin MF, Fahn S, Moskovitz C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 1987; 2: 23754.
  • 9
    Tolosa E, Marti MJ, Kulisevsky J. Botulinum toxin injection therapy for hemifacial spasm. Adv Neurol 1988; 49: 47991.
  • 10
    Scott AB, Kennedy EG, Stubbs HA. Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol 1985; 103: 34750.
  • 11
    Dutton DA, Buckley EG. Long-term results and complications of botulinum A toxin in the treatment of blepharospasm. Ophthalmology 1988; 95: 152934.
  • 12
    American Academy of Ophthalmology. Botulinum treatment of strabismus in children. Ophthalmology 1989; 96: 3741.
  • 13
    Helvestone EM, Pogrebriak AE. Treatment of acquired nystagmus with botulinum A toxin. Am J Ophthalmol 1988; 106: 5846.
  • 14
    Becker-Wegerich P, Rauch L, Ruzicka T. Botulinum toxin A in the therapy of mimic facial lines. Clin Exp Dermatol 2001; 26: 61930.
  • 15
    Pasricha PJ, Ravich WJ, Hendix RT, Sostre S, Jones B, Kalloo AN. Treatment of achalasia with intrasphincteric injection of botulinum toxin: a pilot trial. Ann Intern Med 1994; 121: 5901.
  • 16
    Gui D, Cassetta E, Anastasio G, Bentivoglio AM, Maria G, Albanese A. Botulinum toxin for chronic anal fissure. Lancet 1994; 344: 11278.
  • 17
    Simpson LL. The origin, structure and pharmacologic activity of botulinum toxin. Pharmacol Rev 1981; 33: 15588.
  • 18
    Montecucco C, Schiavo G. Mechanism of action of tetanus and botulinum neurotoxins. Mol Microb 1994; 13: 18.
  • 19
    White JM. Membrane fusion. Science 1992; 258: 91724.
  • 20
    Barinaga M. Secrets of secretion revealed. Science 1993; 260: 4879.
  • 21
    Torbey CF, Singaram C, Bass P, Gaumnitz EA. Action of botulinum toxin on gut smooth muscle involves cholinergic and non-cholinergic neural pathways. Gastroenterology 1997; 112: A840(Abstract).
  • 22
    Bigalke H, Habermann E. Blockade by tetanus and botulinum A toxin of postganglionic cholinergic nerve endings in the myenteric plexus. Naunyn Schmiedebergs Arch Pharmacol 1980; 312: 25563.
  • 23
    MacKenzie J, Burnstock G, Dolly JO. The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience 1982; 7: 9971006.
  • 24
    McKenna J, Dedo H. Cricopharyngeal myotomy: indications and technique. Ann Otol Rhinol Laryngol 1992; 101: 21621.
  • 25
    Buchholz DW. Cricopharyngeal myotomy may be effective treatment for selected patients with neurogenic oropharyngeal dysphagia. Dysphagia 1995; 10: 2558.
  • 26
    Moerman M, Callier Y, Dick C, Vermeersch H. Botulinum toxin for dysphagia due to cricopharyngeal dysfunction. Eur Arch Otorhinolaryngol 2002; 259: 13.
  • 27
    Parameswaran MS, Soliman AMS. Endoscopic botulinum toxin injection for cricopharyngeal dysphagia. Ann Otol Rhinol Laryngol 2002; 111(0): 8714.
  • 28
    Restivo DA, Palmieri A, Marchese Ragona R. Botulinum toxin for cricopharyngeal dysfunction in Parkinson's disease. N Engl J Med 2002; 346(15): 11745.
  • 29
    Haapaniemi JJ, Laurikainen EA, Pulkkinen J, Marttila RJ. Botulinum toxin in the treatment of cricopharyngeal dysphagia. Dysphagia 2001; 16(3): 1715.
  • 30
    Shaw GY, Searl JP. Botulinum toxin treatment for cricopharyngeal dysfunction. Dysphagia 2001; 16(3): 1617.
  • 31
    Ahsan SF, Meleca RJ, Dworkin JP. Botulinum toxin injection of the cricopharyngeus muscle for the treatment of dysphagia. Otolaryngol Head Neck Surg 2000; 122: 6915.
  • 32
    Restivo DA, Marchese Ragona R, Staffieri A, De Grandis D. Successful botulinum toxin treatment of dysphagia in oculopharyngeal muscular dystrophy. Gastroenterology 2000; 119: 1416.
  • 33
    Alberty J, Oelerich M, Ludwig K, Hartmann S, Stoll W. Efficacy of botulinum toxin A for treatment of upper esophageal sphincter dysfunction. Laryngoscope 2000; 110: 11516.
  • 34
    Brant CQ, Siqueira AP, Ferrari AP. Botulinum toxin for oropharyngeal dysphagia: case report of flexible endoscope-guided injection. Dis Esophagus 1999; 12: 6873.
  • 35
    Blitzer A, Brin M. Use of botulinum toxin for diagnosis and management of cricopharyngeal achalasia. Otolaryngol Head Neck Surg 1997; 116: 32830.
  • 36
    Atkinson S, Rees J. Botulinum toxin for cricopharyngeal dysphagia: case reports of CT-guided injection. J Otolaryngol 1997; 26: 2736.
  • 37
    Crary M, Glowasky A. Using botulin toxin A to improve speech and swallowing function following total laryngectomy. Arch Otolaryngol Head Neck Surg 1996; 122: 7603.
  • 38
    Schneider I, Thumfart W, Pototschnig C, Eckel H. Treatment of dysfunction of the cricopharyngeal muscle with botulin A toxin: introduction of a new noninvasive method. Ann Otol Rhinol Laryngol 1994; 103: 315.
  • 39
    Dunne J, Hayes M, Cameron D. Botulinum toxin A for cricopharyngeal dystonia. Lancet 1993; 342: 559.
  • 40
    Wong R, Maydonovitch C, Castell D, eds. The Esophagus. Boston: Little Brown, 1995: 21945.
  • 41
    Richter J, Yamada T, eds. Textbook of Gastroenterology. Philadelphia: Lippincott, 1991: 1083113.
  • 42
    Goldblum J, Rich T, Richter J. Histopathological features in esophagomyotomy specimens from patients with achalasia. Gastroenterology 1996; 111: 64854.
  • 43
    Aggestrup S, Uddman R, Sundler F, et al. Lack of vasoactive intestinal peptide nerves in oesophageal achalasia. Gastroenterology 1983; 84: 9247.
  • 44
    Mearin F, Mourelle M, Guarner F, Papo M, Balboa A, Malagelada JR. Patients with achalasia lack nitric oxide synthase in the gastro-oesophageal junction. Eur J Clin Invest 1993; 23: 7248.
  • 45
    Holloway RH, Dodds WJ, Helm JF, Hogan WJ, Dent J, Arndonfer RC. Integrity of cholinergic innervation to the lower esophageal sphincter in achalasia. Gastroenterology 1986; 90: 9249.
  • 46
    Janssens J, Annese V, Vantrappen G. Medical treatment of primary esophageal motility disorders. Minerva Dietal Gastroenterol 1990; 36: 14555.
  • 47
    Katz PO, Gilbert J, Costell D. Pneumatic dilation is effective long-term treatment for achalasia. Dig Dis Sci 1998; 43: 19737.
  • 48
    Spices A, Kharilas PJ. Treating achalasia from whalebone to laparoscope. J Am Med Assoc 1998; 280: 63842.
  • 49
    Bittinger M, Wienbeck M. Pneumatic dilation in achalasia. Can J Gastroenterol 2001; 15(3): 31, 32, 195–9.
  • 50
    Vaezi MF, Richter JE. Current therapies for achalasia. J Clin Gastroenterol 1998; 27(1): 2135.
  • 51
    Bruley des Varannes S, Scarpignato C. Current trends in the management of achalasia. Digest Liver Dis 2001; 33: 26677.
  • 52
    Nair LA, Parkman HP, Reynolds JC, et al. Complications of pneumatic dilatation: analysis of risk factors, identifying factors and outcome. Dig Dis Sci 1993; 38: 1893904.
  • 53
    Reynolds JC, Parkman HP. Achalasia. Gastroenterol Clin North Am 1989; 18: 22355.
  • 54
    Urbach DR, Hansen PD, Khajanchee YS, Swanstrom LL. A decision analysis of the optimal initial approach to achalasia: laparoscopic Heller myotomy with partial fundoplication, thoracoscopic Heller myotomy, pneumatic dilatation or botulinum toxin injection. J Gastrointest Surg 2001; 5(2): 192205.
  • 55
    Sharp KW, Khaitan L, Scholtz S, Holzman MD, Richards WO. 100 consecutive minimally invasive Heller myotomies: lesson learned. Ann Surg 2002; 235(5): 6318.
  • 56
    Pasricha PJ, Ravich WJ, Hendix RT, Sostre S, Jones B, Kalloo AN. Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med 1995; 322: 7748.
  • 57
    Pasricha PJ, Rai R, Ravich WJ, Hendix RT, Kalloo AN. Botulinum toxin for achalasia: long-term outcome and predictors of response. Gastroenterology 1996; 110: 14105.
  • 58
    Hoffman BJ, Knapple W, Bhutani MS, Aabakken L, Verne GN, Hawes RH. EUS guided injection of botulinum toxin (Botox) for achalasia: final report of an open study. Am J Gastroenterol 1997; 92: 1593.
  • 59
    Neubrand M, Scheurlen C, Schepke M, Sauerbruch T. Long-term results and prognostic factors in the treatment of achalasia with botulinum toxin. Endoscopy 2002; 34: 51923.
  • 60
    Storr M, Born P, Frimberger E, et al. Treatment of achalasia: the short-term response to botulinum toxin injection seems to be independent of any kind of pretreatment. BMC Gastroenterol 2002; 2: 19.
  • 61
    Allescher HD, Storr M, Seige M, et al. Treatment of achalasia: botulinum toxin injection vs pneumatic balloon dilation. A prospective study with long-term follow-up. Endoscopy 2001; 33: 100717.
  • 62
    Mikaeli J, Fazel A, Montazeri G, Yaghoobi M, Malekzadeh R. Randomized controlled trial comparing botulinum toxin injection to pneumatic dilatation for the treatment of achalasia. Aliment Pharmacol Ther 2001; 15: 138996.
  • 63
    D'Onofrio V, Miletto P, Leandro G, Iaquinto G. Long-term follow-up of achalasia patients treated with botulinum toxin. Digest Liver Dis 2001; 33: 10510.
  • 64
    Ghoshal UC, Chaudhuri S, Pal BB, Dhar K, Ray G, Banerjee PK. Randomized controlled trial of intrasphincteric botulinum toxin A injection versus balloon dilatation in treatment of achalasia. Dis Esophagus 2001; 14: 22731.
  • 65
    Annese V, Bassotti G, Coccia G, et al. A multicentre randomised study of intrasphincteric botulinum toxin in patients with esophageal achalasia. Gut 2000; 46: 597600.
  • 66
    Vaezi MF, Richter JE, Wilcox CM, et al. Botulinum toxin versus pneumatic dilatation in the treatment of achalasia: a randomized trial. Gut 1999; 44: 2319.
  • 67
    Muehldorfer SM, Schneider TH, Hochberger J, Martus P, Hahn EG, Ell C. Esophageal achalasia: intrasphincteric injection of botulinum toxin A versus balloon dilation. Endoscopy 1999; 31: 51721.
  • 68
    Kolbasnik J, Waterfall WE, Fachnie B, Chen Y, Tougas G. Long-term efficacy of botulinum toxin in classical achalasia: a prospective study. Am J Gastroenterol 1999; 94: 34349.
    Direct Link:
  • 69
    Wehrmann T, Kokabpick H, Jacobi V, Seifert H, Lembcke B, Caspary WF. Long-term results of endoscopic injections of botulinum toxin in elderly achalasic patients with tortuous megaesophagus or epiphrenic diverticulum. Endoscopy 1999; 31: 3528.
  • 70
    Prakash C, Freedland KE, Chan MF, Clouse RE. Botulinum toxin injections for achalasia can approximate the short term efficacy of a single pneumatic dilation: a survival analysis approach. Am J Gastroenterol 1999; 94: 32833.
    Direct Link:
  • 71
    Annese V, Basciani M, Borrelli O, Leandro G, Simone P, Andriulli A. Intrasphincteric injection of botulinum toxin is effective in long-term treatment of esophageal achalasia. Muscle Nerve 1998; 21: 15402.
  • 72
    Cuillière C, Ducrotté P, Zerbib F, et al. Achalasia: outcome of patients treated with intrasphincteric injection of botulinum toxin. Gut 1997; 41: 8792.
  • 73
    Gordon JM, Eaker EY. Prospective study of esophageal botulinum toxin injection in high risk achalasia patients. Am J Gastroenterol 1997; 92: 18127.
  • 74
    Annese V, Basciani M, Perri F, et al. Controlled trial of botulinum toxin injection versus placebo and pneumatic dilation in achalasia. Gastroenterology 1996; 111: 141824.
  • 75
    Fishman VM, Parkman HP, Schiano TD, et al. Symptomatic improvement in achalasia after botulinum toxin injection of the lower esophageal sphincter. Am J Gastroenterol 1996; 91: 172430.
  • 76
    Rollan A, Gonzalez R, Carvajal S, Chianale J. Endoscopic intrasphincteric injection of botulinum toxin for the treatment of achalasia. J Clin Gastroenterol 1995; 20: 18991.
  • 77
    Anant VKI, Bank S, Greenberg R. Combined intrasphincteric botulinum toxin injection and 25 mm TTS balloon dilatation as a treatment for achalasia of esophagus. Am J Gastroenterol 2000; 95: 24223.
    Direct Link:
  • 78
    Benvenuti S, Felder M, Piazzi L, et al. Use of botulinum toxin in the treatment of esophageal achalasia: medium-term results. Gastroenterology 1999; 116: A122(Abstract).
  • 79
    Annese V, Coccia G, D'Onofrio V, Gatto G, Repici A, Andriulli A. Comparison of two different formulations of botulinum toxin for the therapy of achalasia. Gastroenterology 1999; 116: A953(Abstract).
  • 80
    Mora F, Martinez MT, Minguez M, et al. Treatment of esophageal motor disorders (EMD) with intrasphincteric injection of botulinum toxin (BT): short and long-term outcome. Gastroenterology 1999; 116: A82(Abstract).
  • 81
    Nebendahl JC, Brand B, Von Schrenck T, et al. Prospective randomised comparison of dilation (high compliance balloon) vs botulinum toxin injection (BTX) in esophageal achalasia. Gastroenterology 1998; 114: A240(Abstract).
  • 82
    D'Onofrio V, Annese V, Giardullo N, Marasco A, Andriulli A, Iaquinto G. Long-term follow-up of achalasic patients treated with botulinum toxin. Gastroenterology 1998; 114: A745(Abstract).
  • 83
    Achem SR, Suarez E, Arenas G, Perez-Manauta E, DeVault KR. Comparative treatment of Chagas disease and achalasia with botulinum toxin. Gastroenterology 1998; 114: A844(Abstract).
  • 84
    Vakil D, Ianna E, Batey R, Hewson E. The use of botulinum toxin in achalasia. Gastroenterology 1998; 114: A850(Abstract).
  • 85
    Kozarek RA, Gelfand MD, Patterson DJ, et al. Randomized prospective trial of 50 vs 100 IU botox for achalasia — long term follow-up. Gastroenterology 1997; 112: A184(Abstract).
  • 86
    Stein HJ, Korn O, Kauer W, Dittler HJ, Feussner H, Siewert JR. A step-wise therapeutic strategy for the management of patients with achalasia. Gastroenterology 1997; 112: A1477(Abstract).
  • 87
    Bansal R, Koshy S, Scheiman JM, Barnett JL, Nostrant TT. Interim analysis of a randomized trial of Witzel pneumatic dilation vs intrasphincteric injection of botulinum toxin (Botox) for achalasia. Gastroenterology 1996; 110: A56(Abstract).
  • 88
    Greaves RRSH, Mulcahy HE, Patchett SE, Fairclough PD, Alstead EM, Farthing MJG. Botulinum toxin in the treatment of achalasia. A promise unfulfilled. Gastroenterology 1996; 110: A123(Abstract).
  • 89
    Gaudric M, Guimbaud R, Chaussade S, et al. Pneumatic dilatation (PD) versus intrasphinteric botulinum toxin (BT) in the treatment of achalasia: preliminary results of a controlled study. Gastroenterology 1996; 110: A667(Abstract).
  • 90
    Schroeder P, Slaughter R, Torbey C, Morgan D, Koehler R, Richter J. Treatment of achalasia; botulinum toxin vs pneumatic dilatation. Am J Gastroenterol 1995; 90: A72(Abstract).
  • 91
    Jin HO, Potter GD, Shah AN, Ona FV, Malkin M, Chey WY. Effect of intrasphincteric injection of botulinum toxin on esophageal motility in achalasia. Gastroenterology 1995; 108: A123(Abstract).
  • 92
    Kotfila R, Camp R, Trudeau W. Botulinum toxin (Botox) injection in achalasia patients failing pneumatic dilation and medical therapy. Gastroenterology 1995; 108: A136(Abstract).
  • 93
    Waterfall WE, Tougas G, Fachnie B, Chauhan U. Clinical and manometric response to botulinum toxin (Botox) used as primary treatment for achalasia. Gastroenterology 1995; 108: A255(Abstract).
  • 94
    Hills C, Schiano T, Parkman HP, et al. Botulinum toxin improves symptoms in idiopathic, but not secondary, achalasia. Am J Gastroenterol 1995; 90: 1560.
  • 95
    Gutierrez-Galiana E, Bootoman VA, Bech H. Symptomatic gastroparesis in a patient with achalasia. J Clin Gastroenterol 1998; 27: 1668.
  • 96
    Khurana V, Nehme O, Khurana R, Barkin JS. Urinary retention secondary to detrusor muscle hypofunction after botulinum toxin injection for achalasia. Am J Gastroenterol 2001; 96: 32112.
    Direct Link:
  • 97
    Metchnik L, Somin M, Bergman N, Attali M. Fatal heart block following treatment with botulinum toxin for achalasia. Am J Gastroenterol 2000; 95: 33334.
    Direct Link:
  • 98
    Eaker EY, Gordon JM, Vogel SB. Untoward effects of esophageal botulinum toxin injection in the treatment of achalasia. Dig Dis Sci 1997; 42: 7247.
  • 99
    Horgan S, Hudda K, Eubanks I, McAllister J, Pellegriani CA. Does botulinum toxin injection make oesophagomyotomy a more difficult operation? Surg Endosc 1999; 13: 5769.
  • 100
    Branton SA, DeVault KR, Achem SR, et al. Prior botulinum toxin does not affect laparoscopic myotomy for achalasia. Am J Gastroenterol 1998; 93: 1611.
  • 101
    Imperiale TF, O'Connor JB, Vaezi MF, Richter JE. A cost-minimization analysis of alternative treatment strategies for achalasia. Am J Gastroenterol 2000; 95: 273745.
    Direct Link:
  • 102
    Miller LS, Parkman HP, Schiano TD, et al. Treatment of symptomatic nonachalasia esophageal motor disorders with botulinum toxin injection at the lower esophageal sphincter. Dig Dis Sci 1996; 41: 202531.
  • 103
    Storr M, Allescher HD, Rosch T, Born P, Weigert N, Classen M. Treatment of symptomatic diffuse esophageal spasm by endoscopic injections of botulinum toxin: a prospective study with long-term follow-up. Gastrointest Endosc 2001; 54: 7549.
  • 104
    Mathews S, Cohen H, Kline M. Botulinum toxin injection improves symptomatic hypertensive lower esophageal sphincter. Gastroenterology 1998; 114: A800(Abstract).
  • 105
    Pasricha PJ, Miskovsky EP, Kalloo AN. Intrasphincteric injection of botulinum toxin for suspected sphincter of Oddi dysfunction. Gut 1994; 35: 131921.
  • 106
    Muehldorfer SM, Hahn EG, Ell C. Botulinum toxin injection as a diagnostic tool for verification of sphincter of Oddi dysfunction causing recurrent pancreatitis. Endoscopy 1997; 29: 1204.
  • 107
    Wehrmann T, Seifert H, Seipp M, Lembcke B, Caspary WF. Endoscopic injection of botulinum toxin for biliary sphincter of Oddi dysfunction. Endoscopy 1998; 30: 7027.
  • 108
    Banerjee B, Miedema B, Saifuddin T, Marshall JB. Intrasphincteric botulinum toxin type A for the diagnosis of sphincter of Oddi dysfunction: a case report. Surg Laparosc Endosc Percutan Tech 1999; 9: 1946.
  • 109
    Bertolasi L, Angelini G, Bovo P, et al. Injection of botulinum toxin into the sphincter of Oddi in patients with acute recurrent pancreatitis: an effective ‘medical sphincterotomy’? Gastroenterology 1998; 114: A453(Abstract).
  • 110
    Lund JN, Sholefield JH. Aetiology and treatment of anal fissure. Br J Surg 1996; 83: 133544.
  • 111
    Pescatori M, Interisano A. Annual report of the Italian coloproctology units. Techniques Coloproctol 1995; 3: 2930.
  • 112
    Keighley M, Williams N. Surgery of the Anus, Rectum and Colon. London: W. B. Saunders, 1993.
  • 113
    Abcarian H, Lakshmnam S, Read D, Roccaforte P. The role of the internal sphincter in chronic anal fissure. Dis Colon Rectum 1982; 25: 52530.
  • 114
    Schouten WR, Briel JW, Auwerda JJA. Relationship between anal pressure and anodermal blood pressure. The vascular pathogenesis of anal fissure. Dis Colon Rectum 1994; 37: 6649.
  • 115
    Schouten WR, Briel JW, Auwerda JJA, De Graaf EJR. Ischaemic nature of anal fissure. Br J Surg 1996; 83: 635.
  • 116
    Farouk R, Duthie GS, MacGregor AB, Bartolo DC. Sustained internal anal sphincter hypertonia in patients with chronic anal fissure. Dis Colon Rectum 1994; 37: 4249.
  • 117
    Nelson RL. Meta-analysis of operative techniques for fissure-in-ano. Dis Colon Rectum 1999; 42: 142431.
  • 118
    Garcia-Aguilar J, Montes CB, Perez JJ, Jensen L, Madoff RD, Wong WD. Incontinence after lateral internal sphincterotomy: anatomical and functional evaluation. Dis Colon Rectum 1998; 41: 4237.
  • 119
    Nyam DCNK, Pemberton JH. Long-term results of lateral internal sphincterotomy for chronic anal fissure with particular reference to incidence of fecal incontinence. Dis Colon Rectum 1999; 42: 130610.
  • 120
    Argov S, Levandovsky O. Open lateral sphincterotomy is still the best treatment for chronic anal fissure. Am J Surg 2000; 179: 2012.
  • 121
    Hananel N, Gordon PH. Lateral internal sphincterotomy for fissure-in-ano — revisited. Dis Colon Rectum 1997; 40: 597602.
  • 122
    Oh C, Divino CM, Steinhagen RM. Anal fissure: 20-year experience. Dis Colon Rectum 1995; 38: 37882.
  • 123
    Gorfine SR. Treatment of benign anal disease with topical nitroglycerin. Dis Colon Rectum 1995; 38: 4537.
  • 124
    Watson SJ, Kamm MA, Nicholls RJ, Phillips RKS. Topical glyceryl trinitrate in the treatment of chronic anal fissure. Br J Surg 1996; 83: 7715.
  • 125
    Loder PB, Kamm MA, Nicholls RJ, Phillips RK. ‘Reversible chemical sphincterotomy’ by local application of glyceryl trinitrate. Br J Surg 1994; 81: 121730.
  • 126
    Lund JN, Scholefield JH. A randomised, prospective, double-blind, placebo-controlled trial of glyceryl trinitrate ointment in treatment of anal fissure. Lancet 1997; 349: 114. [Erratum: Lancet 1997; 349: 656.]
  • 127
    Oettlé GJ. Glyceryl trinitrate vs. sphincterotomy for treatment of chronic fissure-in-ano: a randomized, controlled trial. Dis Colon Rectum 1997; 40: 131820.
  • 128
    Bacher H, Mischinger H-J, Werkgartner G, et al. Local nitroglycerin for treatment of anal fissures: an alternative to lateral sphincterotomy? Dis Colon Rectum 1997; 40: 8405.
  • 129
    Kennedy ML, Sowter S, Nguyen H, Lubowski DZ. Glyceryl trinitrate ointment for the treatment of chronic anal fissure: results of a placebo-controlled trial and long-term follow-up. Dis Colon Rectum 1999; 42: 10006.
  • 130
    Dorfman G, Levitt M, Platell C. Treatment of chronic anal fissure with topical glyceryl trinitrate. Dis Colon Rectum 1999; 42: 100710.
  • 131
    Carapeti EA, Kamm MA, McDonald PJ, Chadwick SJD, Melville D, Phillips RKS. Randomised controlled trial shows that glyceryl trinitrate heals anal fissures, higher doses are not more effective, and there is a high recurrence rate. Gut 1999; 44: 72730.
  • 132
    Richard CS, Gregoire R, Plewes EA, et al. Internal sphincterotomy is superior to topical nitroglycerin in the treatment of chronic anal fissure. Results of a randomized, controlled trial by the Canadian Colorectal Surgical Trials Group. Dis Colon Rectum 2000; 43: 104858.
  • 133
    Bassotti G, Clementi M, Ceccarelli F, Pelli MA. Double-blind manometric assessment of two topical glyceryl trinitrate formulations in patients with chronic anal fissures. Digest Liver Dis 2000; 32: 699702.
  • 134
    Altomare DF, Rinaldi M, Milito G, et al. Glyceryl trinitrate for chronic anal fissure: Healing or headache? Results of a multicenter, randomized, placebo-controlled, double-blind trial. Dis Colon Rectum 2000; 43: 17481.
  • 135
    Evans J, Luck A, Hewett P. Glyceryl trinitrate vs. lateral sphincterotomy for chronic anal fissure: prospective, randomized trial. Dis Colon Rectum 2001; 44: 937.
  • 136
    Lysy J, Israelit-Yatzkan Y, Sestiere-Ittah M, et al. Treatment of chronic anal fissure with isosorbide dinitrate: long-term results and dose determination. Dis Colon Rectum 1998; 41: 140610.
  • 137
    Schouten WR, Briel JW, Boerma MO, et al. Pathophysiological aspects and clinical outcome of intra-anal application of isosorbide-dinitrate in patients with chronic anal fissure. Gut 1995; 36: A16(Abstract).
  • 138
    Werre AJ, Palamba HW, Spillenaar Bilgen EJ, Eggink WF. Isosorbide dinitrate in the treatment of anal fissure: a randomised, prospective, double blind, placebo-controlled trial. Eur J Surg 2001; 167: 3825.
  • 139
    Chrysos E, Xynos E, Tzovaras G, et al. Effect of nifedipine on rectoanal motility. Dis Colon Rectum 1996; 39: 2126.
  • 140
    Cook T, Smilgin-Humphreys MM , Mortensen N, et al. Oral nifedipine is an effective treatment for chronic anal fissure. Colorectal Dis 1999; 1: 55.
  • 141
    Antropoli C, Perrotti P, Rubino M, et al. Nifedipine for local use in conservative treatment of anal fissures: preliminary results of a multicenter study. Dis Colon Rectum 1999; 42: 10115.
  • 142
    Brisinda G, Maria G, Sganga G, Bentivoglio AR, Albanese A, Castagneto M. Effectiveness of higher doses of botulinum toxin to induce healing in patients with chronic anal fissures. Surgery 2002; 131: 17984.
  • 143
    Maria G, Brisinda G, Bentivoglio AR, Cassetta E, Gui D, Albanese A. Influence of botulinim toxin site of injection on healing rate in patients with chronic anal fissure. Am J Surg 2000; 179: 4650.
  • 144
    Brisinda G, Maria G, Bentivoglio AR, Cassetta E, Gui D, Albanese A. A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure. N Engl J Med 1999; 341: 659.
  • 145
    Fernandez Lopez F, Conde Freire R, Rios Rios A, Garcia Iglesias J, Cainzos Fernandez M, Potel Lesquereux J. Botulinum toxin for the treatment of anal fissure. Dig Surg 1999; 16: 5158.
  • 146
    Minguez M, Melo F, Espi A, et al. Therapeutic effects of different doses of botulinum toxin in chronic anal fissure. Dis Colon Rectum 1999; 42: 101621.
  • 147
    Jost WH, Schrank B. Chronic anal fissures treated with botulinum toxin injections: a dose-finding study with Dysport. Colorectal Dis 1999; 1: 268.
  • 148
    Madalinski M, Jagiello K, Labon M, Adrich Z, Kryszewski A. Botulinum toxin injection into only one point in the external anal sphincter: a modification of the treatment for chronic anal fissure. Endoscopy 1999; 31: S63.
  • 149
    Maria G, Brisinda G, Bentivoglio AR, Cassetta E, Gui D, Albanese A. Botulinum toxin injections in the internal anal sphincter for treatment of chronic anal fissure: long-term results after two different dosage regimens. Ann Surg 1998; 228: 6649.
  • 150
    Maria G, Cassetta E, Gui D, Brisinda G, Bentivoglio AR, Albanese A. A comparison of botulinum toxin and saline injection for treatment of chronic anal fissure. N Engl J Med 1998; 338: 21720.
  • 151
    Jost WH. One hundred cases of anal fissure treated with botulinum toxin: early and long-term results. Dis Colon Rectum 1997; 40: 102932.
  • 152
    Mason PF, Watkins MJ, Hall HS, Hall AW. The management of chronic fissure in-ano with botulinum toxin. J R Coll Surg Edinb 1996; 41: 2358.
  • 153
    Jost WH, Schimrigk K. Therapy of anal fissure using botulinum toxin. Dis Colon Rectum 1994; 37: 13214.
  • 154
    Siproudhis L, Sebille V, Pigot F, et al. Lack of efficacy of botulinum toxin in chronic anal fissure. Gastroenterology 2000; 118: A176(Abstract).
  • 155
    Espi A, Melo F, Minguez M, et al. Therapeutic use of botulinum toxin in anal fissure (Abstract). Int J Colorectal Dis 1997; 12: 163.
  • 156
    Birkenfeld S, Ron Y, Rozen A, Lokovetzki F, Czerniak A, Avni Y. Treatment of anal fissure with botulinum toxin injections. Gastroenterology 1996; 112: A4(Abstract).
  • 157
    Minguez M, Herreros B, Espi A, et al. Long term follow-up (42 months) of chronic anal fissure after healing with botulinum toxin. Gastroenterology 2002; 123: 1127.
  • 158
    Madalinski MH, Suulawek J, Duzynski W, et al. Side effects of botulinum toxin injection for benign anal disorders. Eur J Gastroenterol Hepatol 2002; 14: 8536.
  • 159
    Lysy J, Israelit-Yatzkan Y, Sestiery-Ittah M, Weksler-Zangen S, Keret D, Goldin E. Topical nitrates potentiate the effect of botulinum toxin in the treatment of patients with refractory anal fissure. Gut 2001; 48: 2214.
  • 160
    Khademi A, Feldman DM. A comparison of combination of botox (botulinum toxin) and nitroglycerin in the treatment of chronic anal fissures. Am J Gastroenterol 2000; 95: A2538(Abstract).
    Direct Link:
  • 161
    Madalinski MH, Slawek J , Zbytek B, et al. Topical nitrates and higher doses of botulinum toxin for chronic anal fissure. Hepatogastroenterology 2001; 48: 9779.
  • 162
    Jost WH. Botulinum toxin type B in the treatment of anal fissures: first preliminary results. Dis Colon Rectum 2001; 44: 17212.
  • 163
    Wiesel PH, Schneider R, Dorta G, Blum AL, Gillet M, Michetti P. Botulinum toxin for refractory postoperative pyloric spasm. Endoscopy 1997; 29: 132.
  • 164
    Miller LS, Szych GA, Kantor SB, et al. Treatment of idiopathic gastroparesis with injection of botulinum toxin into the pyloric sphincter muscle. Am J Gastroenterol 2002; 97: 165360.
    Direct Link:
  • 165
    Lacy BE, Zayat EN, Crowell MD, Schuster MM. Botulinum toxin for the treatment of gastroparesis: a preliminary report. Am J Gastroenterol 2002; 97: 154852.
    Direct Link:
  • 166
    Ezzeddine D, Jit R, Katz N, Gopalswamy N, Bhutani MS. Pyloric injection of botulinum toxin for treatment of diabetic gastroparesis. Gastrointest Endosc 2002; 55: 9203.
  • 167
    Lacy BE, Zayat EN, Crowell MD, Schuster MM. Botulinum toxin for the treatment of gastroparesis. Gastroenterology 2000; 118: A624(Abstract).
  • 168
    Sharma VK, Glassman SB, Howden CW, Vasudeva R. Pyloric intrasphincteric botulinum toxin (BOTOX) improved symptoms and gastric emptying in a patient with diabetic gastroparesis. Am J Gastroenterol 1998; 93: A1742(Abstract).
  • 169
    Lacy BE, Schettler-Duncan VA, Crowell MD. The treatment of diabetic gastroparesis with botulinum toxin. Am J Gastroenterol 2000; 95: A2456(Abstract).
    Direct Link:
  • 170
    De Looze DA, Verdievel HG, Peeters TL, De Vos MM. The pyloric sphincter is back in town. Gastroenterology 2000; 118: A468(Abstract).
  • 171
    Heinen F, Mall V, Ruckauer KD, et al. Lack of response to botulinum toxin A in patients with hypertrophic pyloric stenosis. Eur J Pediatr 1999; 158: 436.
  • 172
    Katsinelos P, Kalomenopoulou M, Christodoulou K, et al. Treatment of proctalgia fugax with botulinum A toxin. Eur J Gastroenterol Hepatol 2001; 13: 13713.
  • 173
    Hallan RI, Williams NS, Melling J, Waldron DJ, Womack NR, Morrison JF. Treatment of anismus in intractable constipation with botulinum A toxin. Lancet 1998; 2: 7147.
  • 174
    Joo JS, Agachan F, Wolff B, Nogueras JJ, Wexner SD. Initial North American experience with botulinum toxin type A for treatment of anismus. Dis Colon Rectum 1996; 39: 110711.
  • 175
    Shafik A, El Sibai O. Botulinum toxin in the treatment of nonrelaxing puborectalis syndrome. Dig Surg 1998; 15: 34751.
  • 176
    Maria G, Brisinda G, Bentivoglio AR, Cassetta E, Albanese A. Botulinum toxin in the outlet obstruction constipation caused by puborectalis syndrome. Dis Colon Rectum 2000; 43: 37680.
  • 177
    Bentivoglio AR, Maria G, Brisinda G, Albanese A. Outlet type constipation in patients with Parkinson's disease treated with botulinum toxin. Mov Disord 2000; 15(S3): 124.